LGALS3 and myeloid sarcoma: Earlier in our study, it was found that the concentration of galectin-3 in patients with MS and no effect from drug antiarrhythmic therapy was 2.6 folds higher than in patients with effective therapy who did not have registered episodes of AF during the observation period [18].